SUVEN PHARMACEUTICALS
|
SUVEN PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 10.52 | 11.79 | 16.16 | 17.83 | 14.23 |
| CEPS(Rs) | 13.44 | 13.94 | 18.04 | 19.36 | 15.48 |
| DPS(Rs) | - | - | 6.00 | 5.00 | 2.00 |
| Book NAV/Share(Rs) | 65.97 | 80.47 | 68.16 | 59.99 | 46.39 |
| Tax Rate(%) | 23.01 | 25.98 | 26.52 | 32.02 | 22.52 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 31.33 | 38.60 | 42.80 | 44.03 | 43.87 |
| EBIT Margin(%) | 29.75 | 39.29 | 42.68 | 51.18 | 47.47 |
| Pre Tax Margin(%) | 28.72 | 38.59 | 41.72 | 50.53 | 46.32 |
| PAT Margin (%) | 22.11 | 28.56 | 30.66 | 34.35 | 35.89 |
| Cash Profit Margin (%) | 28.58 | 33.75 | 34.24 | 37.31 | 39.02 |
| Performance Ratios | |||||
| ROA(%) | 10.02 | 13.76 | 20.18 | 25.62 | 25.26 |
| ROE(%) | 14.20 | 15.87 | 25.21 | 33.52 | 35.78 |
| ROCE(%) | 18.44 | 21.22 | 33.41 | 45.92 | 40.76 |
| Asset Turnover(x) | 0.45 | 0.48 | 0.66 | 0.75 | 0.70 |
| Sales/Fixed Asset(x) | 0.81 | 1.17 | 1.71 | 2.09 | 1.97 |
| Working Capital/Sales(x) | 2.45 | 0.93 | 1.57 | 1.44 | 2.93 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.24 | 0.86 | 0.58 | 0.48 | 0.51 |
| Receivable days | 63.71 | 42.46 | 47.25 | 46.80 | 39.69 |
| Inventory Days | 60.62 | 94.43 | 81.11 | 66.93 | 67.95 |
| Payable days | 74.38 | 65.80 | 79.70 | 87.45 | 94.44 |
| Valuation Parameters | |||||
| PER(x) | 110.23 | 57.37 | 29.26 | 34.66 | 34.80 |
| PCE(x) | 86.28 | 48.54 | 26.20 | 31.91 | 32.01 |
| Price/Book(x) | 17.58 | 8.41 | 6.93 | 10.30 | 10.68 |
| Yield(%) | - | - | 1.27 | 0.81 | 0.40 |
| EV/Net Sales(x) | 24.65 | 16.37 | 8.98 | 11.95 | 12.62 |
| EV/Core EBITDA(x) | 68.05 | 36.80 | 19.39 | 23.41 | 27.87 |
| EV/EBIT(x) | 82.85 | 41.67 | 21.02 | 23.34 | 26.58 |
| EV/CE(x) | 16.63 | 8.24 | 6.67 | 9.72 | 9.64 |
| M Cap / Sales | 24.66 | 16.38 | 8.98 | 11.92 | 12.49 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.91 | -21.56 | 1.52 | 30.75 | 21.10 |
| Core EBITDA Growth(%) | -7.26 | -24.63 | -7.95 | 47.43 | 13.49 |
| EBIT Growth(%) | -13.76 | -27.84 | -15.32 | 41.05 | 12.11 |
| PAT Growth(%) | -11.83 | -26.99 | -9.37 | 25.24 | 14.30 |
| EPS Growth(%) | -10.79 | -27.00 | -9.37 | 25.24 | -42.85 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.05 | 0.02 | 0.04 | 0.06 | 0.12 |
| Current Ratio(x) | 2.34 | 10.67 | 3.81 | 3.64 | 2.07 |
| Quick Ratio(x) | 1.88 | 8.71 | 2.78 | 2.82 | 1.45 |
| Interest Cover(x) | 28.85 | 55.45 | 44.69 | 79.29 | 41.09 |
| Total Debt/Mcap(x) | - | - | 0.01 | 0.01 | 0.01 |
Compare Financial Ratios of peers of SUVEN PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUVEN PHARMACEUTICALS | ₹22,275.0 Cr | -7.5% | -34.7% | -52.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹428,077.0 Cr | 2.8% | 6.3% | -1.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,324.0 Cr | -2.1% | -2.5% | 12.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹126,235.0 Cr | -2.5% | 4.2% | 21.5% | Stock Analytics | |
| CIPLA | ₹123,294.0 Cr | 0% | -3.3% | 0.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,336.0 Cr | 1.3% | -0.5% | -0.2% | Stock Analytics | |
SUVEN PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUVEN PHARMACEUTICALS | -7.5% |
-34.7% |
-52.8% |
| SENSEX | 0.9% |
2.1% |
8.3% |
You may also like the below Video Courses
